MedTrace Logo

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

NCT04450732 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2023-12-05

No results posted yet for this study

Summary

Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors

Conditions

  • HER2-positive Breast Cancer
  • HER2-positive Biliary Tract Cancer
  • HER2-Positive Salivary Gland Carcinomas
  • HER2-Positive Advanced Solid Tumor

Interventions

DRUG

GQ1001

anti-HER2 antibody drug conjugate

Sponsors & Collaborators

  • GeneQuantum Healthcare (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2024-03-01
Completion
2024-05-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450732 on ClinicalTrials.gov